Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Delivra Health Brands is a Canadian specialty pharmaceutical company focused on topical pain relief and dermatological products, operating in the over-the-counter and natural health products segment. The company manufactures and distributes topical analgesics and skin care formulations primarily across North American markets, competing in the fragmented specialty OTC healthcare space. With a micro-cap valuation under $10M and negative cash flow, the stock trades as a speculative turnaround play in the generic/specialty drug manufacturing sector.
Delivra generates revenue through direct sales of branded topical pharmaceutical products to retailers, pharmacies, and e-commerce channels, plus contract manufacturing for private label clients. The 50.7% gross margin suggests moderate pricing power typical of specialty OTC products, though negative operating margins indicate scale challenges and high SG&A burden relative to revenue base. The business model relies on product formulation IP, regulatory approvals (Natural Product Numbers in Canada, potential FDA registrations), and distribution relationships rather than patent-protected exclusivity. Limited pricing power exists due to generic competition in topical analgesics, requiring volume growth and operational efficiency improvements to reach profitability.
New product launches and regulatory approvals (Health Canada NPNs, potential US market entry)
Major retail distribution agreements or contract manufacturing wins
Quarterly revenue growth rates and path to positive operating cash flow
Management commentary on gross margin trends and manufacturing efficiency improvements
Financing announcements or capital raises given negative cash flow position
Regulatory risk from Health Canada and FDA requirements for product approvals, manufacturing standards (GMP compliance), and evolving natural health product regulations that could increase compliance costs
Commoditization pressure in generic topical analgesics market with limited patent protection and low barriers to entry for competing formulations
E-commerce disruption enabling direct-to-consumer brands to bypass traditional retail distribution channels where Delivra currently operates
Competition from well-capitalized multinational pharmaceutical companies (J&J, GSK, Bayer) with established OTC brands, superior marketing budgets, and retail shelf space dominance
Private label expansion by major retailers (Walmart, Shoppers Drug Mart) capturing market share in commodity pain relief categories
Natural health product market fragmentation with hundreds of small competitors and minimal brand loyalty in topical categories
Negative operating cash flow of -$0.5M+ annually creating cash burn and potential need for dilutive equity financing given micro-cap status
Limited financial flexibility with sub-$10M market cap restricting access to institutional capital markets and creating refinancing risk if operating performance deteriorates
Working capital management challenges typical of small manufacturers including inventory obsolescence risk and customer concentration in accounts receivable
low-to-moderate - OTC healthcare products exhibit defensive characteristics as pain relief remains relatively non-discretionary regardless of economic conditions. However, premium-priced natural health products may see modest demand elasticity during recessions as consumers trade down to lower-cost alternatives. The company's small scale and growth stage create higher sensitivity to consumer spending patterns than established pharmaceutical peers. Industrial production and employment levels have indirect impact through retail foot traffic and discretionary health spending.
Rising interest rates create moderate headwinds through two channels: (1) higher financing costs for working capital and potential growth investments given the company's negative cash flow position and 0.50 debt/equity ratio, and (2) valuation multiple compression typical for unprofitable micro-cap growth stocks as risk-free rates increase. The 3.14 current ratio provides liquidity buffer, but sustained rate increases could pressure refinancing terms. Demand side impact is minimal as OTC products are not interest-rate sensitive purchases.
Moderate credit exposure given negative operating cash flow and reliance on working capital financing. Tightening credit conditions could restrict access to revolving facilities needed to fund inventory and receivables. The company's small scale and lack of profitability limit access to institutional credit markets, making it dependent on smaller lenders or equity financing. However, the strong current ratio of 3.14 and relatively low debt/equity of 0.50 suggest manageable near-term credit risk absent significant deterioration in operating performance.
speculative growth - The stock attracts high-risk tolerance investors seeking turnaround opportunities in micro-cap healthcare. Negative profitability, negative cash flow, and -41% three-month return indicate this is not suitable for value or income investors. The 8% revenue growth and 50.7% gross margin suggest potential operating leverage if scale is achieved, appealing to venture-style equity investors willing to accept binary outcomes. Institutional ownership is likely minimal given sub-$10M market cap and lack of liquidity.
high - Micro-cap stocks with negative cash flow and limited liquidity exhibit elevated volatility. The -41% three-month and -29% six-month returns demonstrate significant downside volatility. Low float and limited analyst coverage amplify price swings on company-specific news. Beta likely exceeds 1.5x relative to broader healthcare indices. Daily trading volumes are likely thin, creating execution risk and wide bid-ask spreads.
